Katan Associates Study Shows Long-Awaited Life Sciences Roll-Up Will Continue, as Pharma and Larger Biotechs Hustle to Fill Dwindling Pipelines

Katan Associates Study Shows Long-Awaited Life Sciences Roll-Up Will Continue, as Pharma and Larger Biotechs Hustle to Fill Dwindling Pipelines: "LOS ANGELES--(BUSINESS WIRE)--June 3, 2005--Katan Associates International

Asia and European Union will continue to be fertile breeding ground for M&A transactions

Biotech-driven acquisitions will remain at the forefront of deal activity

'Consolidation will continue among Pharma and Biotech in 2005, whether a true 'roll-up' occurs or not. This activity will be fueled by the need for Pharma to fill the pipeline and the need for Biotech to continue to gain critical mass,' says Seth Yakatan, MBA, Partner, Katan Associates International. 'While the United States has historically been the most active region for deals, Europe and Asia will provide fertile grounds for buyers, given value considerations and a strong lack of mezzanine and secondary capital providers in these markets.'"
======================

Interesting...